Enzo Biochem (ENZ)

[surf1944]

Bought back into ENZ....

[surf1944]

http://www.enzo.com/pressdetailsnew1.asp

[surf1944]

9:01AM Enzo Biochem reports jury declares Life Technologies (LIFE) infringed company patents and awards ENZ $48.6 mln (ENZ halted) (ENZ) 2.30 : Co reported yesterday that the jury in the Enzo action entitled Enzo Biochem vs Applera Corp. and Tropix has rendered its verdict that Applera Corp., now Life Technologies (LIFE) infringed Enzo's patents covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code. The jury awarded $48.6 million in direct infringement penalties. In addition, a pre-judgment award will be awarded by the Court. Attorneys for Enzo estimate that the addition of the pre-judgment award should add additional recoveries of up to tens of millions of dollars. The jury also found that Life Technologies' sequencing instruments induced its customers to infringe Enzo's patent No. 5,449,767. The sales of such instruments are estimated to be $770 million. Enzo plans to seek damages based on the jury decision that the sale of Life Technologies' sequencing instruments induced infringement of Enzo patents. Yale University was also a plaintiff. Enzo expects that today's decision will have a positive impact on the resolution of pending actions that Enzo brought in the U.S. Southern District Court in New York City, which involve additional defendants, patents and contract issues.

Enzo expects that today's decision will have a positive impact on the resolution of pending actions that Enzo brought in the U.S. Southern District Court in New York City, which involve additional defendants, patents and contract issues. Defendants in those suits include Amersham, Amersham Biosciences, Roche Diagnostics (RHHBY), PerkinElmer (PKI), PerkinElmer Life Sciences, Molecular Probes (now owned by Life Technologies), Orchid Cellmark (now owned by Laboratory Corporation of America - LH) and Affymetrix (AFFX).

[surf1944]

One more stock that could be ready to trigger a near-term breakout trade is Enzo Biochem (ENZ), an integrated life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. This stock is off to a bearish start in 2012, with shares off by over 25% during the last six months.

If you look at the chart for Enzo Biochem, you’ll see that this stock hit a near-term bottom in August at around $1.33 a share. Since tagging that bottom, shares of ENZ have started to uptrend towards its current price of around $1.95 a share. During that uptrend, shares of ENZ have been making mostly higher lows and higher highs, which is bullish technical price action. That move is quickly pushing ENZ within range of triggering a near-term breakout trade.

Traders should now look for long-biased trades in ENZ once it manages to clear some near-term overhead resistance levels at $2 to $2.19 a share with high volume. Look for volume off that move that registers near or above its three-month average action of 190,455 shares. If that breakout triggers soon, then ENZ will have a great chance of re-testing or possibly taking out its next major overhead resistance levels at $2.88 to $3.12 a share. Any high-volume move above $3.12 could then put $4 a share into play for ENZ.

One could look to buy ENZ off any weakness, and simply use a stop that sits right around its 50-day moving average of $1.67 a share. You could also just buy off strength once ENZ clears $2.00 to $2.19 a share with high volume, and then simply use a stop around some near-term support at $1.84 a share. Keep in mind that once ENZ clears $2.17 with volume, then it will have taken out its 200-day moving average, which is bullish technical price action.

http://www.stockpickr.com/5-stocks-poised-breakouts.html-18?puc=yahoo&cm_ven=YAHOO

[surf1944]

Labcorp's Acquisition Of Medtox Leaves Enzo As An Attractive Investment Opportunity

http://seekingalpha.com/article/646861-labcorp-s-acquisition-of-medtox-leaves-enzo-as-an-attractive-investment-opportunity?source=yahoo

[mlkrborn]

Recent financials: Still has $15 m cash:

"Enzo Q3 Revenues Flat, Net Loss Widens
June 11, 2012

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Monday that revenues for the fiscal third quarter inched up slightly year over year, but that net loss increased.

During the three months ended April 30, the New York-based company recorded $25.9 million in revenues, up from $25.8 million in the year-ago period. Clinical laboratory services increased to $15.2 million, up 10percent from $13.8 million, but product revenues slid 12 percent to $9.6 million from $10.9 million. Royalty and licensing fees were essentially flat at $1.1 million.

In its Form 10-Q filed with the US Securities and Exchange Commission, Enzo said that R&D costs shrank 24 percent year over year to $1.6 million from $2.1 million, while SG&A costs grew 9 percent to $11.9 million from $10.9 million a year ago.

Enzo's net loss for the third quarter was $3.4 million, or $.09 per share, compared to a net loss of $2.1 million, or $.05 per share, a year ago.

The company finished the quarter with $15.3 million in cash, cash equivalents, and short-term investments. "

[mlkrborn]

spiked to $2.00 no obvious reason. Must be pounding shorties!

[surf1944]

2:24AM Enzo Biochem presents new AmpiProbe nucleic acid amplification platform details; data suggests highly efficient and economic platform could be basis for next-generation molecular diagnostics (ENZ) 2.69 : Co announces it made its first peer-reviewed presentation of its novel AmpiProbe platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays. The assay was found to be highly specific to HCV, showing no cross reactivity to other infectious viruses and no susceptibility to potentially interfering substances associated with clinical samples. In addition, the AmpiProbe HCV RNA assay was found, as compared to similar diagnostics products, to achieve a greater enhanced sensitivity that allows for a more convenient and efficient workflow requiring significantly less starting material. The data also suggests that it may facilitate paneling of multiple independent assays from the standard amount of starting material.

[surf1944]

7:24AM On The Wires (WIRES) : Enzo Biochem (ENZ) announced an expanded business arrangement between its wholly owned subsidiary, Enzo Life Sciences, and Tokyo-based Cosmo Bio Co.

[surf1944]

7:03AM Enzo Biochem's clinical laboratory applies for NY State Health Department approval for first assay based on its AmpiProbe amplification platform (ENZ) 2.81 : Co announced the filing of an application with the New York State Department of Health for the first assay based on its proprietary AmpiProbe nucleic acid detection platform. Upon approval, the Company plans to market its HCV RNA Quantification Assay for viral load determination through its Enzo Clinical Laboratory.

[surf1944]

Enzo Biochem Receives Approval for Novel Blood Based Test for Colorectal Cancer Risk

New York State Approves ColonSentry™ RNA Expression Assay

First in Pipeline of Unique Products to be offered through Company’s Clinical Laboratory
Business WirePress Release: Enzo Biochem, Inc. – Tue, Feb 21, 2012 8:37 AM EST

NEW YORK--(BUSINESS WIRE)--

Enzo Biochem, Inc. (NYSE:ENZ - News) today announced that the New York State Department of Health has approved Enzo Clinical Labs’ use of the ColonSentry™ test for providing an assessment of a patient’s risk of having colorectal cancer. The ColonSentry™ test was originally developed by GeneNews (TSX: GEN.TO - News) and requires only a small blood sample which can be collected during a routine blood draw. Enzo plans to begin offering the assay to its clientele in March 2012.

The ColonSentry™ test uses RNA contained in blood to measure the level of the expression of seven genes. These genes serve as biomarkers whose levels can reflect the current presence or severity of a disease state. Interpretation of the status of these seven biomarkers can allow physicians to identify patients who have an increased current risk of having colorectal cancer. The test requires only a small sample of blood and can thus be easily incorporated as a pre-screening measure into routine yearly physical exams.

“The approval of this assay underscores the execution of our strategic plan to build our company into a unique developer and provider of high value molecular and esoteric products and services”, said Barry Weiner, President of Enzo Biochem. "By utilizing the technological and assay development expertise of our Life Sciences group along with the translational medicine capabilities we have built at Enzo Clinical Labs, we have been able to develop a robust pipeline of products and technologies designed for today’s healthcare market. We expect to announce additional developments arising from Enzo’s unique integrated operating structure in the weeks ahead. Presently, Enzo Biochem is the only lab in the US that is approved to offer this assay.”

"With respect to ColonSentry™, we can now provide physicians with a new tool for their patients in assessing their risk for having colorectal cancer with a simple blood test. The information provided by this test can guide their recommendation for a colonoscopy. We know that patient compliance for colonoscopies is low—the ColonSentry™ test is a non-invasive method that provides strong guidance to recommend a colonoscopy. Evidence supported recommendations can lead to higher compliance, potentially contributing to earlier detection of colorectal cancer and fewer deaths,” he added.

Dr. Joseph Felder, a Gastroenterologist in New York City said, "Identifying a higher risk for colon cancer in a given patient may give us a way to improve compliance with colonoscopy in those who are hesitant to be screened."

About Colon Cancer

According the American Cancer Society, colorectal cancer is the third leading cause of cancer-related deaths in the United States when men and women are considered separately, and the second leading cause when both sexes are combined. It is expected to be the central cause of about 49,380 deaths in 2011.

In addition, excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society's most recent numbers estimate 101,700 new cases of colon cancer and 39,510 new cases of rectal cancer in the United States in 2011. Overall, the lifetime risk of developing colorectal cancer is about 1 in 20. This risk is slightly lower in women than in men.

There are a number of risk factors for colon cancer including age, a history of colon polyps, inflammatory bowel disease, diabetes, obesity and a family history of colon cancer. Lifestyle risks include smoking, a diet that is high in red meats and processed meats, physical inactivity and heavy alcohol use.

Early detection of colon cancer is considered the best way to improve a patient’s chance of survival. While 90% of colorectal cancer cases can be cured if detected early, the 5 year survival rate drops to 10% when detected late.

[surf1944]

http://quotes.barrons.com/enz/ownership

[surf1944]

4:14PM Enzo Biochem reports Q4 (ENZ) 2.85 +0.01 : Reports Q4 (Jul) earnings of ($0.11) per share, $0.05 worse than the Capital IQ Consensus Estimate of ($0.06); revenues rose 7.6% year/year to $26.8 mln vs the $26.4 mln consensus.

[surf1944]

Enzo Biochem Appoints Four Executives at Enzo Life Sciences as Unit Adds Products and Platforms to More Aggressively Expand in Pharmaceutical and Clinical Markets

Chart for Enzo Biochem, Inc. Common Stock
Press Release Source: Enzo Biochem Inc. On Monday August 22, 2011, 10:00 am EDT

NEW YORK--(BUSINESS WIRE)-- Enzo Biochem Inc. (NYSE:ENZ - News) announced today that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.

The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D’Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.

Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary’s operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo’s presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.

“Enzo Life Sciences has developed numerous new products to meet the demands of these exciting growth markets and our investment in people—which we are announcing today—is a manifestation of our commitment to this exciting strategy. All four individuals are highly experienced, with technical expertise and impressive professional and commercial accomplishments; we are confident they will all make notable contributions to our Company’s growth,” says Barry Weiner, Enzo Biochem President.

Among the additions to Enzo Life Sciences’ offerings is a line of specific products and assays aimed at, among other areas, epigenetics, a burgeoning new approach to studying genetic variations in treatments and drug discoveries among large and small pharma.

Enzo Life Sciences’ emphasis is increasingly on developing platforms and products to meet the expanding needs of new and revolutionary pharmacological and genetic treatments, which often require extensive pre-clinical testing. In addition, these added capabilities will materially enhance the broader esoteric diagnostic direction at Enzo Clinical Labs, another subsidiary of Enzo Biochem, which is itself focused on greater national recognition and expanding the use of its higher value molecular testing capabilities.

The new Enzo Life Science appointments include:

Bruce Taillon, PhD, as head of global technology business development. He previously was associated with Roche Diagnostics’ 454 Life Sciences Division, where he was responsible for world-wide business development efforts centered around the company’s next generation nucleic acid sequencing platform and its potential use in diagnostic assays. He also has experience in leading R&D teams focused in the areas of genomics, proteomics and drug development.

John D’Errico, PhD, He will lead the Company’s commercial merchandising operations. Dr. D’Errico joins Enzo from VWR Scientific, where he managed that company’s life sciences product portfolio. He also brings extensive product management and M&A expertise from Harvard Biosciences, where he headed business development efforts at Genomic Solutions, a Life Science tools company.

Kara Cannon. Ms. Cannon was appointed head of Enzo Life Science’s global marketing, joining the Company after 10 years at Pall Corporation, where she held executive positions in the areas of diagnostics, biotechnology and biosciences. She has had extensive experience in the marketing and selling of innovative platforms for the diagnostics markets as well as the development and execution of strategic plans for the growth and sustainability of diagnostic-related businesses.

Paul Munger, PhD, Dr. Munger will lead Enzo Life Sciences’ Global Manufacturing Operations. He previously held an executive position at Pierce Chemical, now a division of Thermo Fisher, as well as a senior manufacturing management role at Transgenomic, Inc, where he was responsible for scaling up drug intermediate candidates that led to substantial cost reductions while raising quality and reducing turnaround time. Most recently Paul led the US-based manufacturing of regulated diagnostic kits for Idexx Labs.

[surf1944]

8:02AM Enzo Biochem scientists report on key discovery of novel targets for metabolic bone disease and other conditions (ENZ) 4.41 : Co reported that scientists from its Enzo Therapeutics group presented a podium session entitled "The Presence of Sulfated Tyrosine In Scelerostin and Dkk1 Ligands and its Effect on Wnt Signaling" at the WNT 2011 conference in Los Angeles Thursday, June 30, 2011. The work performed by Enzo's scientific team showed the existence of an entirely new class of modification of scelerostin and Dkk proteins which exhibit significant biological function. These proteins have been shown to inhibit the Wnt signaling pathway, and therefore mediate the development of numerous diseases. As an example, fluctuation in the level of these proteins has been shown to affect such serious conditions as osteoporosis. It has been reported that anti-scelerostin anabolics are among the most exciting development in the treatment of bone disorders.

[surf1944]

http://www.nasdaq.com/asp/holdings.asp?symbol=ENZ&selected=ENZ&FormType=Institutional

[surf1944]

http://www.secform4.com/insider-trading/316253.htm

[surf1944]

Enzo Biochem gets rights to potential HPV test
Enzo Biochem plans to market test designed to find cervical cancer risk in HPV patients

On Friday June 10, 2011, 2:45 pm EDT

NEW YORK (AP) -- Enzo Biochem Inc. said Friday that it agreed to acquire the marketing rights to a human papillomavirus test developed by IncellDx Inc.

The company said the test is designed to assess the likelihood that a patient with HPV will develop cervical cancer. Regulators have not yet cleared the test, and Enzo said it will conduct studies of the test before seeking New York State approval. The company said it will be the first New York licensed reference laboratory to offer the test.

Enzo did not disclose financial terms of the deal.

HPV is responsible for about 70 percent of all cervical cancer cases. The virus spreads through sexual contact.

Enzo Biochem reported its fiscal third-quarter results on Thursday. It posted a smaller quarterly loss and said revenue rose 9 percent.

In afternoon trading Friday, the stock rose 18 cents, or 4.9 percent, to $3.89.

[surf1944]

http://www.enzo.com/pressdetailsnew1.asp

[bpvitale]

NGNM – Strong Buy at $1.10

ENZ shareholders may also want to pay attention to NGNM, another small cancer diagnostics company.

NGNM just reported solid third quarter results, with revenue growth of 19% YoY and volume growth of 29% YoY. I think management did a great job on the conference call and seem to be making all of the right moves. With much of the heavy lifting now behind the company, business should begin to improve each quarter going forward, and probably one of the reasons why management was comfortable enough to provide 2011 estimates. NGNM now expects 2011 revenues to be in the range of $41-45 million, which would imply a 25-30% increase in sales next year, and an increase from the 15-18% expected revenue growth in 2010.

Clearly, the business has bottomed and the business model has reached critical mass.

NGNM at $1.10 is way undervalued and great opportunity for any small-cap investor, and I still believe NGNM is going to be a big winner, even more than ever, after listening to the third quarter conference call.

[B7$4]

"ENZ News" Enzo Biochem Says Favorable Patent Appeals Court Decision Will Allow Pursuit of Claim for Substantial Damages

http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=18722

Enzo Biochem Inc. (NYSE:ENZ) said today that a decision released Friday by the Court of Appeals for the Federal Circuit reversing a district court’s summary judgment will enable the Company to pursue a claim for substantial damages against Applera Corporation, now Life Technologies Corporation. (NASDAQ: LIFE). The Court of Appeals vacated the lower court’s judgments of invalidity on United States Patent Nos. 5,328,824 and 5,449,767.

The asserted patents cover pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code. The complaint against Applera Corporation and its subsidiary Tropix Inc. charged patent infringement arising out of the misappropriation of Enzo’s proprietary and pioneering patented technologies related to DNA sequencing systems, and other products, as well as providing others with unauthorized and prohibited access to the patented products and technologies.

“The Appellate Court’s ruling clears the way for us to pursue claims related to the broad scope of the products subject to our patents, and substantially weakens the defense of Applera with respect to their potential liability,” said Elazar Rabbani, PhD, Enzo Chairman and CEO. “This decision allows us to seek redress in terms of claims for damages. When the Federal Circuit mandate issues in about three weeks, remanding the case to the District Court in New Haven, Connecticut, and assuming Applera does not seek rehearing or reconsideration, we will be able to promptly move forward with our case.”

Additionally, the Court of Appeals affirmed the lower court’s ruling that a construction of U.S. Patent No. 5,082,930 was not infringed and that U.S. Patent No. 5,476,918 was invalid. These rulings will not affect Enzo’s claims against Applera, since Enzo believes that Applera’s products are covered by US Patents 5,328,824 and/or 5,449,767.

About Enzo Biochem

Read more: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=18722#ixzz0jew1zv3N

[mlkrborn]

2.70-7.50 52 weeks range! now $5.50s

[mlkrborn]

ENZO will shed assets to concentrate on cancer research only!

[Hedge Starz]

whats up with this one

[RonnieD]

They have zero debt, 76 million in cash and a mkt cap of only 150m (double their cash).

http://finance.yahoo.com/q/pr?s=ENZ

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in research, development, manufacturing, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Life Sciences, Therapeutics, and Clinical Labs. The Life Sciences segment manufactures, develops, and markets biomedical research products and tools to research and pharmaceutical customers. It offers products applied in the fields of gene expression, non-radioactive labeling and detection, adipokines and obesity, apoptosis, bioactive lipids, cell cycle, cytoskeletal research, DNA damage and repair, epigenetics, immunology and cancer research, inflammation, neurobiology, nitric oxide and oxidative stress, and signal transduction. The Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene therapy technologies for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 23 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. Enzo Biochem sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, and internationally. The company was founded in 1976 and is headquartered in New York, New York.

[AXXel Knutson]

Enzo Biochem reinstated Coverage ENZ-12.99 with "Strong Buy"
Axxel Knutson, President & Chief Investment Officer [CIO] of TradingWeapon.com in Warren, New Jersey, an OSJ* office of First Allied Securities Inc., an NASD/SIPC member, today re-initiated coverage of Enzo Biochem, Inc. ENZ-12.99] with a "Strong Buy" recommendation. TradingWeapon.com is located at 197 Mountainview Road, Warren, New Jersey 07059 TEL: [phone].

· Office of Supervisory Jurisdiction FAS is a non-bank affiliate of Wells Fargo & Co.

[Joemoney]

Enzo Biochem Reports Strong Gains in Fourth Quarter and Fiscal 2001 Operating Results

FARMINGDALE, N.Y.--(BUSINESS WIRE)--Oct. 29, 2001--Enzo Biochem, Inc. (NYSE: ENZ - news), a leading biotechnology company specializing in gene identification and gene regulation technologies for diagnostic and therapeutic applications, today reported strong gains in revenues and sharply increased pre-tax income for the fiscal fourth quarter and 12 months ended July 31, 2001.

For the fourth quarter, total revenues increased 8.4%, to $15.5 million, compared with $14.3 million in the corresponding year-earlier period. Income before interest and taxes increased 50.2%, to $2.5 million, and operating income advanced 27.1%, to $3.1 million. Despite a higher tax rate, the result of the Company utilizing tax loss carryforwards, net income for the period amounted to $1.7 million, compared with $1.6 million in the corresponding year-earlier period, a gain of 6.3%. Per share net income equaled $0.06 in both the fiscal 2001 and 2000 fourth quarters.

For all of fiscal 2001, total revenues increased 16.7%, to $58.4 million, a gain of $8.4 million. Income before interest and taxes rose 81.6%, to $9.2 million, and operating income for the full year advanced 59.5%, to $12.2 million. Fiscal 2001 net income amounted to $6.8 million, compared with $6.6 million the prior year, up 2.8%. Per share net income rose to $0.24, on 28.1 million diluted weighted average shares outstanding, compared with $0.23, on 28.3 million diluted weighted average shares outstanding in the previous year. The effective tax rate in fiscal 2001 was 44.3%, compared to 13.6% in the previous year.

A Year of Solid Growth

``Fiscal 2001 was another year of solid growth for Enzo Biochem,'' said Barry Weiner, President. ``Results benefited from a strong performance in research product sales, which continue to demonstrate increased unit growth. We continued to achieve significant advances in therapeutics and life sciences, while revenues and profits maintained their upward momentum. We launched several new life sciences products for the genomics market and we were awarded an important new pioneering patent in the realm of nucleic acid diagnostics. In therapeutics we initiated a new Phase II clinical study for hepatitis B virus infection (HBV), we began a Phase I trial of our proprietary immune regulation medicine for hepatitis C virus infection (HCV) and we began the initiation phase of a Phase I clinical study for individuals suffering from Crohn's disease. We reported outstanding accomplishments in the Phase I clinical trial of HGTV43, our proprietary gene medicine for HIV-1 infection, in which all subjects treated with HGTV43 experienced extended engraftment of the transduced cells, a dramatic achievement for Enzo and gene therapy generally.''

Life Sciences and Enzo Labs Post Gains

Revenues in Life Sciences increased 25% in fiscal 2001, benefiting especially from sales of a growing roster of BioArray(TM) products, particularly for the genomics field. Gross profit margins for Life Sciences rose to 70% from 59% last year. Clinical laboratory services revenues advanced 11.9% this year, reflecting the addition of new patient service centers and a larger customer roster among physicians.

Expenditures for research and development in fiscal 2001 totaled $6.1 million, a 12% increase over the prior year. With continuing strong cash flow, working capital at the end of fiscal 2001 amounted to $85 million, including cash and cash equivalents of $59 million, up from $51 million 12 months earlier. Equity capital amounted to $98 million. There was no debt.

During the year, Enzo was awarded U.S. Patent No. 6,221,581 directed to innovative nucleic acid formatting applicable to diagnostics and genetic analyses. The Company noted at the time that ``this far-reaching patent adds yet another component to the Company's vast technological capabilities and intellectual property estate.'' The Japanese Patent Office also upheld, in an opposition proceeding, Enzo's patent covering a key segment of the Company's gene identification program.

Widening Roster of Clinical Trials

We began a Phase I clinical study of EHC18 our proprietary immune regulation medicine for hepatitis C virus infection and we began the initiation process of a Phase I clinical study for individuals suffering from Crohn's disease.

A Phase II clinical study of EHT899, Enzo's immune regulation medicine for treatment of HBV infection, with an estimated 350 million people worldwide at risk of death from inflammatory liver disease resulting from HBV, is continuing. Approximately 75% of the study subjects have shown favorable results in one or more of the key indicators used to measure progress in treating HBV.

These clinical trials are based on continued extensive preclinical research in animal model systems. Results of some of the research - for treatment of colitis and of hepatocellular carcinoma - using Enzo's immune regulation medicines were reported at several scientific meetings during the past year.

HGTV43, Enzo's HIV-1 gene medicine product, is expected to begin expanded Phase I-II studies at multiple sites. The Company has reported that all five of the HIV-1 infected individuals who were treated with HGTV43 in the Phase 1 trial at the University of California San Francisco and are now in the follow-up phase of the trial continue to tolerate the procedure well and demonstrate extended engraftment of the transduced cells, at least two of them for over 22 months. This is believed to be a first in the field of gene therapy involving unablated adult patients.

About Enzo

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis with approximately 200 patents worldwide are sold to the life sciences market throughout the world. The Company's therapeutic division is conducting clinical trials for HIV-1-infected patients and for patients infected with hepatitis B and hepatitis C viruses. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes.

Except for historical information, the matters discussed in this news release may be considered ``forward-looking'' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

A conference call conducted by Enzo Biochem, Inc. management will take place on October 30, 2001 at 8:30 A.M. (ET). It can be accessed by dialing 800-921-9431. You may also listen over the Internet through Investor Broadcast Networks' Vcall website, located at www.vcall.com. To listen to the live call on the Internet, please go to the web site at least fifteen minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available through midnight November 5, 2001, shortly following the live call. For replay, dial 973-341-3080. You will be prompted for PIN number 2922859.

(tables to follow)

ENZO BIOCHEM, INC.
SELECTED STATEMENT OF OPERATIONS DATA

Fiscal Year Ended Three Months Ended
July 31, July 31,
2001 2000 2001 2000
unaudited
(in thousands)

Operating revenues $58,406 $50,029 $15,470 $14,274

Income before
provision for
income taxes $12,231 $7,668 $3,108 $2,446

Provision for
income taxes $5,418 $1,043 $1,394 $861
------ ------- ------ ----

Net income $6,813 $6,625 $1,714 $1,585
====== ====== ====== ======

Net income per
common share - Basic $0.25 $0.25 $0.06 $0.06
===== ===== ===== =====

Net income per
common share - Diluted $0.24 $0.23 $0.06 $0.06
----- ----- ----- -----

Common Share - Basic 26,999 26,597 27,026 26,576

Common Share - Diluted 28,126 28,335 28,105 28,294


ENZO BIOCHEM, INC.
SELECTED BALANCE SHEET DATA

July 31, 2001 July 31, 2000
(In Thousands) (In Thousands)


Cash and Cash
Equivalents $58,671 $51,027

Working Capital $85,094 $74,094

Stockholders' Equity $97,517 $87,176


--------------------------------------------------------------------------------
Contact:
Enzo Biochem, New York
Steve Anreder, 212/532-3232

http://biz.yahoo.com/bw/011029/292562_1.html

[Joemoney]

Enzo reports benefits in Phase II for hepatitis drug

NEW YORK, Oct. 12 (Reuters) Enzo Biochem, Inc. (NYSE:ENZ - news), a developer of genetically engineered health-care products on Friday said a drug for treating sufferers of chronic hepatitis B has shown benefits in 75 percent of infected subjects in Phase II clinical trials.

The New York-based company said data from a clinical trial indicated that individuals treated with the oral immune regulation therapy for hepatis B virus (HBV) showed improvement in key indicators of liver inflammation.

Other improvements occurred in biopsy results, HBV viral load, liver enzymes and histology, the company said.

Decreases in HBV viral load and improvement in liver function tests were observed in 46 percent of the trial subjects. Biopsy scores improved in 58 percent of the subjects, and histological improvement in liver necroinflammatory score was registered in 33 percent.

The safety data indicate that the drug, designated EHT899, was well tolerated in all subjects, Enzo said, adding the trial involved 42 individuals who were treated orally with EHT899 three times a week for 20 to 30 weeks, and followed for an additional 20 more weeks. The trial is ongoing and the subjects are continually being evaluated. Enzo shares closed on Thursday at $19.85 on the New York Stock Exchange.

http://biz.yahoo.com/rf/011012/n12305316_1.html

[Joemoney]

Enzo Biochem Reports Improvement in Key Indicators Among Subjects in Phase II Hepatitis B Study

NEW YORK--(BW HealthWire)--Oct. 12, 2001--Enzo Biochem, Inc. (NYSE: ENZ - news) today reported preliminary results of its Phase II clinical trial of EHT899, the Company's proprietary medicine for treating patients suffering from chronic active hepatitis associated with hepatitis B virus (``HBV'').

The data indicate that the individuals treated with this oral immune regulation therapy showed improvement in key indicators of liver inflammation.

Approximately 75% of the HBV-infected subjects thus far treated orally with Enzo's EHT899 in the Phase II trial experienced improvement in one or more of the key end point parameters, including biopsy results, HBV viral load, liver enzymes and histology. Decreases in HBV viral load and improvement in liver function tests were observed in 46% of the trial subjects. Biopsy scores improved in 58% of the subjects, and histological improvement in liver necroinflammatory score was registered in 33%. The safety data indicate that the drug was well tolerated in all subjects.

The trial is ongoing and the subjects are continually being evaluated. These data are consistent with previously reported results of 15 subjects, of which 80% showed similar improvement.

``We are obviously encouraged by these findings,'' said Barry Weiner, President of Enzo. He commented on a recently published abstract of the Phase II trial to be presented at a meeting next month of the American Association for the Study of Liver Disease, during remarks delivered this morning at the UBS Warburg Global Life Sciences Conference here.

In the trial, 42 individuals were treated orally with EHT899 three times a week for 20 to 30 weeks, and followed for an additional 20 weeks. The trial was conducted at Hadassah Medical Center in Jerusalem, Israel. An estimated 350 million people worldwide suffer from hepatitis B and inflammatory livers, and therefore are at risk of death of liver disease.

Mr. Weiner, in his presentation, also discussed the current clinical trial for HGTV43, Enzo's proprietary genetic medicine treatment for HIV-infected individuals, where plans are proceeding for expanded trials and additional sites. In addition, Mr. Weiner commented on the status of other human clinical trials of Enzo's immune regulation therapy for individuals suffering from chronic active hepatitis associated with hepatitis C virus, hepatocellular cancer and Crohn's Disease. He also outlined in detail the activity of Enzo Life Sciences, and the Company's pioneering position in the field of genomics and Enzo's opportunities in the growing $2 billion clinical diagnostic field.

A recording of the full presentation can be accessed over the next four weeks by dialing 1-877-710-5304 (domestic) and 1-402-220-0702 (international).

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis with approximately 200 patents worldwide are sold to the life science market throughout the world. The Company's therapeutic division is conducting clinical trials for HIV-1-infected patients, for patients infected with hepatitis B virus, and hepatitis C and its related hepatocellular carcinoma (liver cancer). Other therapeutic applications of Enzo's proprietary technology are directed towards the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes.

Except for historical information, the matters discussed in this news release may be considered 'forward-looking`` statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

http://biz.yahoo.com/bw/011012/120083_1.html

[Joemoney]

ENZ has rallied big in the past few weeks and if this keeps up, it will reach it's resistance around 38. If this is broken we may see old highs.

Good luck!
joe

[Joemoney]

Enzo Biochem Awarded Pioneering Patent In U.S. With Wide Application for Nucleic Acid Diagnostics and Testing
FARMINGDALE, N.Y.--(BW HealthWire)--May 14, 2001--Enzo Biochem, Inc. (NYSE:ENZ - news) announced today that the United States Patent and Trademark Office has awarded the Company U.S. Patent No. 6,221,581 directed to innovative nucleic acid formatting applicable to diagnostics and genetic analyses.

Enzo said that the newly patented diagnostic technology can be used as a platform for multiple applications including the diagnosis of infectious diseases and cancer as well as for use in complex genetic analyses and will provide a simple cost effective method applicable to the diagnosis of both direct and amplified specimens, a potential market in excess of $500 million.

``This far-reaching patent adds yet another component to the Company's vast technological capabilities and intellectual property estate encompassing more than 200 patents and a similar number of patent applications,'' said Elazar Rabbani, Chairman and CEO of Enzo. ``It provides Enzo with an important new position in an area of diagnostics which is receiving a great deal of attention, and it has significant potential which we have every intention of fully exploiting.''

One aspect of the patent covers a unique format involving binding unlabeled nucleic acid probes to specific targets which are then isolated or captured on a surface. The bound targets are then detected using labeled protein molecules, such as antibodies. The Company said that the formats covered by the patent permit accurate and sensitive detection and quantification of pathogens, including viruses. It is particularly applicable to measuring viral loads in subjects being monitored for viral diseases. Enzo said that plans are already underway to commercialize the format and to bring new products incorporating its features to market.

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis with approximately 200 patents worldwide are sold to the life science market throughout the world. The Company's therapeutic division is conducting clinical trials for HIV-1-infected patients and for patients infected with hepatitis B and hepatitis C viruses, and suffering from hepatitis C- associated hepatocellular carcinoma (liver cancer). Other therapeutic applications of Enzo's proprietary technology are directed towards cholesterol management and the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes.

Except for historical information, the matters discussed in this news release may be considered ``forward-looking'' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.